US 2025/0026853 A1Published application

Humanized anti-muc1* antibodies

AssigneeMinerva Biotechnologies Corporation

InventorsCynthia Bamdad, Benoit Smagghe

Life of this patent

Estimating the term…

Abstract

The present application discloses humanized antibodies and antibody like proteins and fragments thereof.

Claims18

Dependent claims

A method of treating a MUC1* positive cancer in a subject comprising administering immune cells that express a MUC1* targeting chimeric antigen receptor (CAR) to the subject.

Dependencies are inferred from the claim text.

Facts

Application: 18/644,795Filed 24 Apr 2024
Priority: 10 Feb 2015
Published: 23 Jan 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification18 codes

C07K 16/3092
Against structure-related tumour-associated moieties: against tumour-associated mucins
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]
A61K 40/32
Characterised by the recombinant expression of specific molecules in the cells of the immune system: t-cell receptors [TCR]

Family

Application62/114,526Us provisional application · filed 10 Feb 2015
Application15/549,942Continuation · filed 9 Aug 2017
Application17/817,525Division · filed 4 Aug 2022
Application18/644,795Division
Application17/817,525Continuation
US 11,746,159 B2Related patent
US 12,006,371 B2Related patent
US 2018/0112007 A1Published application
US 2023/0183373 A1Published application
US 2025/0026853 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results